Home | Welcome to Contract Pharma   
Last Updated Friday, May 22 2015


AstraZeneca to Buy Respiratory Drug Company, Amirall

Published August 1, 2014

AstraZeneca has bought the Catalan company, Amirall's, respiratory therapies business, including rights to Eklira, a drug that is designed to treat chronic obstructive pulmonary disease (COPD) and represents 14.4% of the company's total sales. The Catalan News Agency reported this news on Wednesday, July 30, 2014.

AstraZeneca will reportedly pay $875 million initially, and up to $1.22 billion, depending on product development success, new product launches and sales.  "A significant number of employees" will reportedly be transferred to AstraZeneca, the news agency reported.   

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On